ACE2 and dengue disease: It has been used in the production of a number of bioactive vaccines, including a dengue fever vaccine candidate derived from the consensus domain III (cEDIII) of dengue glycoprotein E [174,175], and therapeutic proteins, such as human EPO [176,177,178,179], human osteopontin (OPN) [180], and human angiotensin-converting enzyme 2 (ACE2), against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [181].